RenovoRx, Inc. RNXT
1.66
(0.02)
(1.19%)
as of 25 Sep
- Market cap
- $75.8M
- P/E
- 0.0×
Follow RNXT
Insider Buys
alert about insiders buying in the last 12 month
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (125.23%) | (100.47%) | (225.62%) | (146.61%) |
+8 more TTM periods Free account |
|
| (97.83%) | (81.85%) | (137.77%) | (104.58%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(136.20%) | (103.30%) | (187.92%) | (121.91%) | |
Average Days of Receivables |
88.66 | 68.64 | 45.18 | 0.00 | |
Free Cash Flow per Share |
(0.25) | (0.30) | (0.31) | (0.28) | |
Free Cash Flow |
(11.94) | (11.30) | (10.97) | (10.40) | |
Capital Expenditures |
(0.07) | — | 0.00 | (0.01) | |
Piotroski F-Score |
3.00 | 4.00 | 4.00 | 1.00 | |
| Other line items | |||||
Cash ROIC |
(64.29%) | (47.83%) | (88.16%) | (57.30%) | |
Accounts Receivable Turnover |
4.69 | 5.71 | 12.34 | — | |
Accounts Payable Turnover |
0.40 | 0.30 | 0.47 | 0.39 | |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
1,026.27 | 1,288.44 | 891.85 | 1,050.28 | |
Days of Inventory on Hand |
453.88 | 436.39 | 210.96 | 328.74 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
284.87% | 393.22% | 558.24% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
484.77% | 549.76% | 626.63% | 0.00% | |
Share Based Compensation of Revenue |
76.97% | 87.04% | 112.82% | 0.00% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.97 | 0.92 | 0.98 | 0.94 | |
Depreciation/Fixed assets |
0.06 | 0.03 | 0.17 | 0.08 | |
Capex/Depreciation |
(11.83) | 0.00 | (1.00) | (14.00) | |
Revenue per Share |
0.04 | 0.04 | 0.03 | 0.00 | |
Operating CF per Share |
(0.25) | (0.30) | (0.31) | (0.28) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.04 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
(621.71%) | (823.98%) | (994.48%) | 0.00% |
Columns are period end dates